{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:51:34Z","timestamp":1791215494414,"version":"4.1.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"abstract":"\n Importance<\/jats:title>\n Preventing irreversible disability accumulation is a primary treatment goal in multiple sclerosis (MS).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess 10-year safety and efficacy of ocrelizumab (OCR) in patients with relapsing MS (RMS).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In 2 phase 3 multicenter randomized clinical trials (OPERA I and II), patients were randomized to OCR or interferon beta-1a (IFN) throughout a 2-year double-blind period (DBP) and entered an open-label extension (OLE) to receive OCR for up to an additional 8 years. Study periods were August 2011 to December 2022, with clinical cutoff on July 15, 2023. Data analyses were run between March 2023 and May 2026. Patients with RMS, aged 18 to 55 years, with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, and at least 1 relapse within the year before screening were eligible for inclusion.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n OCR (600 mg every 24 weeks) or IFN (44 \u00b5g 3 times weekly) in the DBP, then OCR during the OLE.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes included time to onset of 48-week confirmed disability progression (CDP) or progression independent of relapse activity (PIRA); time to reach EDSS score of 4.0 and 6.0; relapse rates; and incidence of adverse events (AEs) and serious AEs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1656 patients were randomized, and 1651 patients received either OCR (n\u2009=\u2009825) or IFN (n\u2009=\u2009826). A total of 1325 patients (80.0%) entered the OLE, of whom 853 (64.4%) completed the studies. A total of 1093 of 1656 patients (66.0%) were female; mean (SD) baseline age was 37.1 (9.2) years vs 37.2 (9.2) years in the OCR vs IFN arms, respectively. Over 10 years, continuous OCR (OCR-OCR) significantly reduced the hazard of 48-week CDP by 24% compared with delayed initiation (IFN-OCR; hazard ratio, 0.76; 95% CI, 0.61-0.95;\n P<\/jats:italic>\n \u2009=\u2009.02), with 680 patients (82.2%) receiving OCR-OCR remaining free of 48-week CDP and 712 (86.1%) free of PIRA. OCR-OCR treatment reduced the hazard of progressing to key disability milestones, including EDSS of 4.0 (34%; hazard ratio, 0.66; 95% CI, 0.43-1.03;\n P<\/jats:italic>\n \u2009=\u2009.06) and 6.0 (43%; hazard ratio, 0.57; 95% CI, 0.40-0.82;\n P<\/jats:italic>\n \u2009=\u2009.002), with 502 (93.3%) and 774 (94.2%) retaining scores less than 4.0 and 6.0, respectively. In patients receiving OCR-OCR, relapse rates decreased from 0.139 at year 1 to 0.016 at year 10. Rates of AEs and SAEs, including serious infections, did not increase over the 8-year OLE.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In the OPERA I and II randomized clinical trials, continuous OCR treatment over 10 years provided greater benefit in preserving function than a 2-year delay in initiating OCR, reinforcing the importance of early high-efficacy treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial Registrations<\/jats:title>\n \n ClinicalTrials.gov Identifiers:\n NCT01247324<\/jats:ext-link>\n and\n NCT01412333<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.3507","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:44Z","timestamp":1791212444000},"source":"Crossref","is-referenced-by-count":0,"title":["Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis"],"prefix":"10.1001","author":[{"given":"Stephen L.","family":"Hauser","sequence":"first","affiliation":[{"name":"UCSF Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[{"name":"Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre of Catalonia, Department of Neurology-Neuroimmunology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun-Frenay","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences Scl\u00e9rose en Plaques (CRC-SEP) Nice, Neurologie CHU Nice, H\u00f4pital Pasteur 2, C\u00f4te d\u2019Azur Joint Clinical Research Unit (UMR2CA)\u2013Unit\u00e9 de Recherche sur le syndrome Radiologique ISol\u00e9 (URRIS), Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyana","family":"Amezcua","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Villar","sequence":"additional","affiliation":[{"name":"Department of Immunology, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada"},{"name":"NeuroRx Research, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology and Department of Neurology, University Medical Centre, G\u00f6ttingen, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita e Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Pasquarelli","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Chognot","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Martin","family":"Schneble","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licinio","family":"Craveiro","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[{"name":"Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"10","key":"noi260064r1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi260064r2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WCO.0000000000001063","article-title":"New drugs for multiple sclerosis: new treatment algorithms.","volume":"35","author":"Cree","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"noi260064r3","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.","volume":"269","author":"Filippi","year":"2022","journal-title":"J Neurol"},{"issue":"9","key":"noi260064r4","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability.","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"2","key":"noi260064r5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ana.27270","article-title":"New horizons for multiple sclerosis therapy: 2025 and beyond.","volume":"98","author":"Sabatino","year":"2025","journal-title":"Ann Neurol"},{"issue":"3","key":"noi260064r8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"noi260064r9","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"noi260064r10","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/ene.14823","article-title":"Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials.","volume":"29","author":"Giovannoni","year":"2022","journal-title":"Eur J Neurol"},{"issue":"5","key":"noi260064r11","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis.","volume":"14","author":"Hauser","year":"2025","journal-title":"Neurol Ther"},{"issue":"4","key":"noi260064r12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaneurol.2026.0007","article-title":"Five years of ublituximab in multiple sclerosis: ULTIMATE I and II open-label extension study.","volume":"83","author":"Cree","year":"2026","journal-title":"JAMA Neurol"},{"issue":"2","key":"noi260064r13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00415-015-7978-y","article-title":"Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.","volume":"263","author":"Kappos","year":"2016","journal-title":"J Neurol"},{"issue":"10","key":"noi260064r14","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1177\/13524585211033190","article-title":"Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.","volume":"27","author":"Hartung","year":"2021","journal-title":"Mult Scler"},{"issue":"7","key":"noi260064r15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis.","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr Treat Options Neurol"},{"issue":"12","key":"noi260064r16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis.","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"issue":"10","key":"noi260064r17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies.","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"noi260064r18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"22","key":"noi260064r19","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"key":"noi260064r20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2018.12.014","article-title":"Multiple sclerosis and cancer incidence: a Danish nationwide cohort study.","volume":"28","author":"N\u00f8rgaard","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"noi260064r22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2019.05.010","article-title":"Lifespan normative data on rates of brain volume changes.","volume":"81","author":"Battaglini","year":"2019","journal-title":"Neurobiol Aging"},{"issue":"6","key":"noi260064r23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/13524585231162586","article-title":"Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.","volume":"29","author":"Kolind","year":"2023","journal-title":"Mult Scler"},{"issue":"1","key":"noi260064r25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200349","article-title":"Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab.","volume":"12","author":"Vukusic","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"noi260064r26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation.","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol"},{"issue":"9","key":"noi260064r27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/13524585241267211","article-title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.","volume":"30","author":"Roos","year":"2024","journal-title":"Mult Scler"},{"issue":"Pt 11","key":"noi260064r30","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis.","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"issue":"8","key":"noi260064r31","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s10072-024-07449-0","article-title":"Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.","volume":"45","author":"Lorefice","year":"2024","journal-title":"Neurol Sci"},{"key":"noi260064r32","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104941","article-title":"Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.","volume":"79","author":"Alroughani","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"noi260064r33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.msard.2015.09.002","article-title":"Relapses in multiple sclerosis: relationship to disability.","volume":"6","author":"Goodin","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"noi260064r34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/1531-8249(199907)46:1<79::AID-ANA12>3.0.CO;2-9","article-title":"Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy.","volume":"46","author":"van Walderveen","year":"1999","journal-title":"Ann Neurol"},{"issue":"1","key":"noi260064r35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2009.01221.x","article-title":"Black holes in multiple sclerosis: definition, evolution, and clinical correlations.","volume":"122","author":"Sahraian","year":"2010","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"noi260064r36","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210049","article-title":"Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: the phase IIIb ENSEMBLE 4-year, single-arm, open-label trial.","volume":"103","author":"Hartung","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"noi260064r37","first-page":"1330","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.","volume":"93","author":"Zhu","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi260064r38","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105570","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss multiple sclerosis centers.","volume":"86","author":"Diem","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"noi260064r39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10","key":"noi260064r40","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5?years.","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult Scler"},{"issue":"9","key":"noi260064r41","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders.","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"noi260064r42","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104245","article-title":"Serious infections in patients with relapsing and progressive forms of multiple sclerosis: a German claims data study.","volume":"68","author":"Knapp","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"noi260064r43","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis.","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult Scler"},{"key":"noi260064r44","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: a multi-database study.","volume":"41","author":"Persson","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"noi260064r46","doi-asserted-by":"crossref","DOI":"10.1002\/ana.78286","article-title":"Comparable infection risk of ocrelizumab and rituximab in multiple sclerosis in a nationwide Swedish cohort study.","author":"Frisell","year":"2026","journal-title":"Ann Neurol"},{"issue":"1","key":"noi260064r48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.78033","article-title":"Comparative safety profiles of ocrelizumab and rituximab in multiple sclerosis treatment using real-world evidence.","volume":"99","author":"Cerono","year":"2026","journal-title":"Ann Neurol"},{"issue":"10","key":"noi260064r49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/13524585251367611","article-title":"Immunosenescence in multiple sclerosis: new insights and clinical implications.","volume":"31","author":"Laroni","year":"2025","journal-title":"Mult Scler"},{"key":"noi260064r50","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241277736","article-title":"Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.","volume":"17","author":"Derfuss","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"noi260064r51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/eurpub\/ckt044","article-title":"Public health surveillance with electronic medical records: at risk of surveillance bias and overdiagnosis.","volume":"23","author":"Chiolero","year":"2013","journal-title":"Eur J Public Health"},{"key":"noi260064r52","article-title":"Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry.","volume":"48","author":"Bast","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"noi260064r45","author":"Carlson","year":"2025"},{"key":"noi260064r47","author":"Butzkueven","year":"2025"},{"key":"noi260064r6","unstructured":"Ocrevus (ocrelizumab). Prescribing information. Genentech; 2025. Accessed May 11, 2026. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf"},{"key":"noi260064r7","unstructured":"Ocrevus (ocrelizumab): annex I: summary of product characteristics. European Medicines Agency. Accessed July 16, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf"},{"key":"noi260064r21","unstructured":"Surveillance, Epidemiology, and End Results Program. US National Institutes of Health. Accessed October 24, 2024. https:\/\/seer.cancer.gov"},{"key":"noi260064r24","unstructured":"Guidelines for data registration. European Commission. Accessed February 9, 2026. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/data-collection\/guidelines-for-data-registration_en"},{"key":"noi260064r28","unstructured":"US Food and Drug Administration. What is a serious adverse event? Accessed March 12, 2026. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"noi260064r29","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Accessed March 12, 2026. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2854792\/jamaneurology_hauser_2026_oi_260064_1790362604.16711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:47Z","timestamp":1791212447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2854792"}},"subtitle":["The OPERA I and II Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.3507","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}